newsfilter
← Latest News
GlobeNewswire·

Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market

MEDIA RELEASE CIMERLI®*, a ranibizumab biosimilar, is interchangeable with LUCENTIS®** (ranibizumab injection) for all approved indicationsDedicated retina sales and field reimbursement team